MetaCap

Cingulate (CING) vs Gossamer Bio (GOSS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed Gossamer Bio (GOSS) over the past year, gaining 27.8% versus a loss of 95.6%. Cingulate is the larger company by market cap ($67.5 million vs $65.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%GOSS-95.62%
+247%+67%-113%
Nov 21, 20251 yearNov 20, 2026
CING-99.49%GOSS-98.69%
+46%-30%-107%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus GOSS key metrics
MetricCINGGOSS
Share price$4.51$10.72
Market cap$67.48M$65.57M
1-day change-14.26%-4.54%
YTD return+3.92%-95.68%
1-year return+27.76%-95.62%
5-year return—-98.74%
EPS (TTM)$-2.67$-42.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$48.47M
Revenue growth (YoY)—-57.74%
Net income (latest FY)$-22.45M$-170.37M
Operating margin—-352.23%
Net margin—-351.49%
52-week high$11.89$309.60
52-week low$3.16$8.29
Distance from 52-week high-62.07%-96.54%
Analyst consensusnonebuy
Avg. price target upside+370.07%+669.40%
Average volume178.82K243.40K
Shares outstanding14.96M6.12M
Employees14161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CING has outperformed GOSS by 123.4 percentage points over the past year.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

CING vs GOSS FAQ

Which is bigger, Cingulate or Gossamer Bio?

Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $65.57M for Gossamer Bio (GOSS).

Which stock has performed better over the past year, CING or GOSS?

CING returned +27.76% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and Gossamer Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons